- Jonathan Ross Hart

Jonathan Ross Hart

The Scripps Research Institute
BCC 239
10550 North Torrey Pines Road
La Jolla, CA 92037



  1. Hart JR, Garner AL, Yu J, Ito Y, Sun M, Ueno L, Rhee JK, Baksh MM, Stefan E, Hartl M, Bister K, Vogt PK, Janda KD. Inhibitor of MYC identified in a Kröhnke pyridine library. Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12556-61.
  2. Valeri N, Braconi C, Gasparini P, Murgia C, Lampis A, Paulus-Hock V, Hart JR, Ueno L, Grivennikov SI, Lovat F, Paone A, Cascione L, Sumani KM, Veronese A, Fabbri M, Carasi S, Alder H, Lanza G, Gafa' R, Moyer MP, Ridgway RA, Cordero J, Nuovo GJ, Frankel WL, Rugge M, Fassan M, Groden J, Vogt PK, Karin M, Sansom OJ, Croce CM. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell. 2014 Apr 14;25(4):469-83
  3. Vogt PK, Hart JR. PI3K and STAT3: a New Alliance. Cancer Discovery 2011;1:481-486.
  4. Sun M, Hart JR, Hillmann P, Gymnopoulos M, Vogt PK. Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide 3-kinase. Cell Cycle 2011;10(21):3731-9.
  5. Hart JR, Liao L, Yates JR, Vogt PK. "Essential role of Stat3 in PI3K-induced oncogenic transformation." Proc. Natl. Acad. Sci. U.S.A.. 2011;108(32):13247-52.
  6. Hart JR, Vogt PK. "Phosphorylation of AKT: a Mutational Analysis." Oncotarget. 2011;2(6):467-76.
  7. Hart JR, Liao L, Ueno L, Yates JR, Vogt PK. "Protein expression profiles of C3H 10T1/2 murine fibroblasts and of isogenic cells transformed by the H1047R mutant of phosphoinositide 3-kinase (PI3K)." Cell cycle (Georgetown, Tex.). 2011;10(6):971-6.
  8. Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, Zhao L, Denley A. Phosphatidylinositol 3-Kinase: The Oncoprotein. In: Rommel C, Vanhaesebroeck B, Vogt PK, editors. Curr Top Microbiol Immunol. 2010;347:79-104. PMCID: 2955792. PMID: 20582532.
  9. Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK. "Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha." Proc. Natl. Acad. Sci. U.S.A.. 2010;107(35):15547-52.
  10. Dannemann N, Hart JR, Ueno L, Vogt PK. "Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic." Int. J. Cancer. 2010;127(1):239-44.
  11. Vogt PK, Gymnopoulos M, Hart JR. "PI 3-kinase and cancer: changing accents." Curr. Opin. Genet. Dev.. 2009;19(1):12-7.
  12. Vogt PK, Hart JR. "Akt demoted in glioblastoma." Science signaling. 2009;2(67):pe26.
  13. Denley A, Gymnopoulos M, Hart JR, Jiang H, Zhao L, Vogt PK. "Biochemical and biological characterization of tumor-associated mutations of p110alpha." Meth. Enzymol.. 2008;438:291-305.
  14. Hart JR, Glebov O, Ernst RJ, Kirsch IR, Barton JK. "DNA mismatch-specific targeting and hypersensitivity of mismatch-repair-deficient cells to bulky rhodium(III) intercalators." Proc. Natl. Acad. Sci. U.S.A.. 2006;103(42):15359-63.
  15. Hart JR, Johnson MD, Barton JK. "Single-nucleotide polymorphism discovery by targeted DNA photocleavage." Proc. Natl. Acad. Sci. U.S.A.. 2004;101(39):14040-4.
  16. Rüba E, Hart JR, Barton JK. "[Ru(bpy)2(L)]Cl2: luminescent metal complexes that bind DNA base mismatches." Inorg Chem. 2004;43(15):4570-8.
  17. Junicke H, Hart JR, Kisko J, Glebov O, Kirsch IR, Barton JK. "A rhodium(III) complex for high-affinity DNA base-pair mismatch recognition." Proc. Natl. Acad. Sci. U.S.A.. 2003;100(7):3737-42.

Professional Presentations


  1. Barton, J.K., Zeglis, B., Lau, I.H., Hart, J.R., Lim, M.H. Compounds and methods for nucleic acid mismatch detection. US Patent #7,786,298, Aug. 31, 2010